REG - Medica Group PLC - Director/PDMR Shareholding

MedicaAnnouncement

08/11/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221108:nRSH7148Fa&default-theme=true

RNS Number : 7148F  Medica Group PLC  08 November 2022

Medica Group PLC

 

Director / PDMR Shareholding

 

Medica Group PLC (the "Company") announces that on 7 November 2022, the PDMRs
listed below were granted options over ordinary shares of 0.2p each in the
Company under the Company's Deferred Bonus Plan 2017 at a nil exercise price:

 

 Name of PDMR     Number of shares subject to option
 Stuart Quin                          87,409
 Richard Jones                        61,700
 Kevin Terrins                        38,181
 Sarah Burns                          38,181
 Marc O'Brien                         46,275

 Caroline Byrne                       21,389

 Rob Lavis                            24,722

 

The notifications set out below are provided in accordance with the
requirements of the UK Market Abuse Regulation, and set out more details of
the transactions.

 

 1.   Details of PDMR
 (a)  Name                                     1.           Stuart Quin

                                               2.           Richard Jones

                                               3.           Kevin Terrins

                                               4.           Sarah Burns

                                               5.           Marc O'Brien

                                               6.           Caroline Byrne

                                               7.           Rob Lavis

 2.   Reason for notification
 (b)  Position / status                        1.           Chief Executive Officer

                                               2.           Chief Financial Officer

                                               3.           Group Director of Corporate Development

                                               4.           Managing Director, UK

                                               5.           Chief Information Officer

                                               6.           Managing Director, Ireland

                                               7.           Group Medical Director

      Initial notification / amendment         Initial notification in each case
 3.   Details of the Issuer
 (a)  Name                                     Medica Group PLC
 (b)  LEI                                      213800B8XE5FUSZF5Z16
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transaction(s) have been conducted
 (a)  Description of the financial instrument  Ordinary shares of 0.2p each in the capital of the Company ("Shares")
 (b)  Nature of the transaction                Grant of options to acquire Shares pursuant to the Company's Deferred Bonus
                                               Plan 2017
 (c)  Price(s) and volume                      Option Price nil in each case

                                               1.          87,409

                                               2.          61,700

                                               3.          38,181

                                               4.          38,181

                                               5.          46,275

                                               6.          21,389

                                               7.          24,722

 (d)  Aggregated information                   N/A
 (e)  Date of the transaction                  7 November 2022
 (f)  Place of the transaction                 Outside a trading venue

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBKFBBNBDDDDK